Related Experiment Video

Updated: Nov 25, 2025

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

858

Lipid Metabolism and Resistance to Anticancer Treatment

Nicolas Germain1,2, Mélanie Dhayer1, Marie Boileau1,3

  • 1UMR 9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France.

Biology
|December 19, 2020
PubMed

Insights

Cancer cells reprogram metabolism to fuel growth and resist therapies. This review explores how altered lipid metabolism drives anticancer drug resistance and suggests targeting these pathways to improve treatment outcomes.

Area of Science:

  • Oncology
  • Metabolic pathways
  • Cancer biology

Background:

  • Metabolic reprogramming is essential for cancer cell survival and proliferation.
  • Metabolic alterations influence sensitivity to chemotherapy and targeted therapies.
  • Emerging evidence links lipid metabolism changes to anticancer drug resistance.

Purpose of the Study:

  • To review the role of lipid metabolism alterations in mediating resistance to anticancer agents.
  • To discuss the significance of these metabolic changes in cancer therapy.
  • To explore strategies for exploiting dysregulated lipid metabolism to overcome drug resistance.

Main Methods:

  • Literature review of studies on cancer metabolism and drug resistance.
  • Analysis of key lipid metabolic pathways implicated in therapy resistance.
  • Synthesis of current understanding and future directions.

Main Results:

  • Specific alterations in lipid metabolism pathways are associated with resistance to various anticancer drugs.
  • These lipid metabolic changes provide survival advantages to cancer cells under therapeutic pressure.
  • Targeting lipid metabolism presents a promising strategy to re-sensitize resistant tumors.

Conclusions:

  • Dysregulated lipid metabolism is a significant mechanism of anticancer drug resistance.
  • Modulating lipid metabolism holds potential for novel therapeutic interventions.
  • Further research into cancer lipid metabolism is crucial for developing effective combination therapies.
Keywords:
antimetabolic cooperativitycancer drug resistancelipid metabolismsynthetic lethality

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.2K
Assessment of the Metabolic Profile of Primary Leukemia Cells06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
17.2K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
80